Meicelin

Meiselin (Beijing Meiselin Pharmaceutical Technology) is a Chinese pharmaceutical company specializing in the research, development, and commercialization of drugs for digestive and inflammatory conditions. The company is best known for its focus on Mesalazine-based therapies, which are widely used in the treatment of inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. Beyond its core gastrointestinal portfolio, Meiselin engages in the development of chemical drugs targeting cardiovascular diseases and oncology. The company operates as an integrated entity with capabilities spanning from early-stage drug discovery to clinical development and market distribution within the Chinese healthcare sector.